Catalyst Pharmaceuticals (NASDAQ:CPRX) Hits New 12-Month High - Time to Buy?

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Get Free Report) reached a new 52-week high on Monday . The stock traded as high as $26.58 and last traded at $25.99, with a volume of 451337 shares trading hands. The stock had previously closed at $25.87.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on the company. Stephens restated an "overweight" rating and set a $33.00 price target on shares of Catalyst Pharmaceuticals in a research note on Thursday, February 27th. Cantor Fitzgerald raised Catalyst Pharmaceuticals to a "strong-buy" rating in a report on Thursday, June 5th. HC Wainwright restated a "buy" rating and set a $35.00 price objective on shares of Catalyst Pharmaceuticals in a research report on Friday, February 28th. Wall Street Zen raised Catalyst Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research report on Friday, February 28th. Finally, Robert W. Baird lifted their price target on shares of Catalyst Pharmaceuticals from $28.00 to $32.00 and gave the stock an "outperform" rating in a research note on Monday, March 3rd. Six equities research analysts have rated the stock with a buy rating and three have assigned a strong buy rating to the stock. Based on data from MarketBeat, the company has an average rating of "Buy" and a consensus price target of $32.83.

Catalyst Pharmaceuticals Stock Down 4.4%

The company has a market capitalization of $2.96 billion, a price-to-earnings ratio of 20.58, a P/E/G ratio of 3.31 and a beta of 0.72. The business has a fifty day simple moving average of $23.81 and a two-hundred day simple moving average of $22.85.

Insider Buying and Selling

In other Catalyst Pharmaceuticals news, insider Preethi Sundaram sold 1,600 shares of the stock in a transaction dated Wednesday, June 11th. The shares were sold at an average price of $26.42, for a total transaction of $42,272.00. Following the sale, the insider now owns 41,081 shares of the company's stock, valued at $1,085,360.02. This represents a 3.75% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Gary Ingenito sold 200,000 shares of the business's stock in a transaction dated Tuesday, May 13th. The stock was sold at an average price of $23.68, for a total transaction of $4,736,000.00. Following the completion of the transaction, the insider now directly owns 68,873 shares of the company's stock, valued at approximately $1,630,912.64. This represents a 74.38% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 247,924 shares of company stock worth $5,879,369 in the last quarter. 10.40% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Catalyst Pharmaceuticals

A number of large investors have recently modified their holdings of CPRX. Steward Partners Investment Advisory LLC bought a new position in Catalyst Pharmaceuticals in the 4th quarter worth approximately $27,000. Park Square Financial Group LLC acquired a new stake in shares of Catalyst Pharmaceuticals in the 4th quarter valued at $29,000. Farther Finance Advisors LLC raised its position in shares of Catalyst Pharmaceuticals by 125.1% during the fourth quarter. Farther Finance Advisors LLC now owns 2,690 shares of the biopharmaceutical company's stock worth $56,000 after acquiring an additional 1,495 shares during the last quarter. Sound Income Strategies LLC bought a new stake in shares of Catalyst Pharmaceuticals during the first quarter worth $64,000. Finally, Wilmington Savings Fund Society FSB acquired a new position in shares of Catalyst Pharmaceuticals during the fourth quarter valued at $65,000. 79.22% of the stock is currently owned by institutional investors and hedge funds.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.